[1] Das DK. Serous effusions in malignant lymphomas: a review. Diagn cytopathol. 2006; 34 (5): 335-347.
[2] Patel T, Patel P, Mehta S, et al. The value of cytology in diagnosis of serous effusions in malignant lymphomas: an experience of a tertiary care center. Diagn cytopathol. 2019; 47 (8): 776-782.
[3] Savvidou K, Dimitrakopoulou A, Kafasi N, et al. Diagnostic role of cytology in serous effusions of patients with hematologic malignancies. Diagn cytopathol. 2019; 47 (5): 404-411.
[4] Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985; 56 (4): 905-909.
[5] Jing X, Li QK, Bedrossian U, Michael CW. Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods. Am J Clin Pathol. 2013; 139 (2): 177-182.
[6] Jones D, Weinberg DS, Pinkus GS, Renshaw AA. Cytologic diagnosis of primary serous lymphoma. Am J Clin Pathol. 1996; 106 (3): 359-364.
[7] Alexandrakis MG, Passam FH, Kyriakou DS, Bouros D. Pleural effusions in hematologic malignancies. Chest. 2004; 125 (4): 1546-1555.
[8] Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008; 111:2962-2972.
[9] Tong LC, Ko HM, Saieg MA, et al. Subclassification of lymphoproliferative disorders in serous effusions: A 10-year experience. Cancer cytopathol. 2013; 121 (5): 261-270.
[10] Gong X, Lu X, Xiao X, et al. Clinicopathologic characteristics of prefibrotic early primary myelofibrosis in Chinese patients. Hum Pathol. 2014; 45: 498-503.
[11] Cheng Y, Wang Y, Wang H, Chen Z et al. Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia. 2009; 23: 1801- 1806.
[12] Li J, Zhang W, Zhao S, et al. The Accuracy of diagnosing burkitt lymphoma in serous effusion specimen: A cytological-histological correlation with ancillary studies. Cytopathology. 2019; 30 (4): 378-384.
[13] McKenna RW, Kyle RA, Kuehl WM, et al. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC. 2017: 241-258.
[14] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391-405.
[15] Gong X, Yu T, Tang Q, et al. Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study. Int J Lab Hematol. 2019; 41(3): 380-386.
[16] Santos GC, Longatto-Filho A, Carvalho LV, et al. Immunocytochemical study of malignant lymphoma in serous effusions. Acta Cytol. 2000; 44(4): 539-542.
[17] Chou WC, Tang JL, Lin LI, Yao M et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res. 2006; 66(6): 3310-3316.
[18] Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome: the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007; 139(3):405-414.
[19] Gong X, Lu X, Wu X, et al. Role of bone marrow imprints in hematological diagnosis: a detailed study of 3781 cases. Cytopathology. 2012; 23(2):86-95.
[20] Jiang Y, Xie W, Hu K, et al. An aggressive form of non-Hodgkin's lymphoma with pleural and abdominal chylous effusions: A case report and review of the literature. Oncol let. 2013; 6 (4): 1120-1122.
[21] Shirai T, Hashizume I, Kasamatsu N, et al. A case of bence-Jones protein-lambda positive multiple myeloma complicated by abnormal plasma cells in pleural effusion. Nihon Kokyuki Gakkai Zasshi. 1998; 36: 176-181.
[22] Uchiyama K, Kobayashi Y, Tanaka R, et al. Primary malignant lymphoma of the central nervous system presenting with ascites and pleural effusion. Hematologica (Budap). 2000; 30: 143-148.
[23] Watanabe N, Sugimoto N, Matsushita A, et al. Association of intestinal lymphoma and ulcerative colitis. Intern Med. 2003; 42: 1183-1187.
[24] Su X-Y, Huang J, Jiang Y, et al. Serous effusion cytology of extranodal natural killer/T-cell lymphoma. Cytopathology. 2011; 23 (2): 96-102.
[25] Gascoyne RD, Campo E, Jaffe ES, et al. Diffuse large B-cell lymphoma, NOS. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC. 2017: 291-297.
[26] Chen YP, Huang HY, Lin KP, et al. Malignant effusions correlate with poorer prognosis in patients with diffuse large B-cell lymphoma. Am J Clin Pathol. 2015; 143 (5): 707-715.
[27] Harbhajanka A, Brickman A, Park J, et al. Cytomorphology, clinicopathologic, and cytogenetics correlation of myelomatous effusion of serous cavities: A retrospective review. Diagn Cytopathol. 2016; 44 (9): 742-747.
[28] Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351: 1860-1873.
[29] Kintzer JS Jr, Rosenow EC 3rd, Kyle RA: Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med. 1978; 138: 727-730.
[30] Iannitto E, Minardi V, Tripodo C. Use of intrapleural bortezomib in myelomatous pleural effusion. Br J Haematol. 2007; 139: 621–622.